Trial Profile
A multicenter Phase III study of GB232 in patients with autoimmune disorder
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
- 03 Jan 2017 New trial record